mercredi 7 novembre 2018

Onco Actu du 7 novembre 2018

1. Biologie

Fishing for new leads in a rare melanoma [Boston Children's Hospital]

4.12 Biopsies liquides

Fishing for tumour DNA in the liquid bathing the brain [Cancer Research UK]

4.9 Dép., diag. & prono. - Sein

Social media scheme boosts breast cancer screening uptake [PharmaTimes]

5.12 Immunothérapies

Single-cell analysis reveals how melanoma cells resist immunotherapy [Dana-Farber Cancer Institute]

5.12.10 Immunothérapies - Fusions et acquisitions

Are more immuno-oncology buyouts on the menu at Eli Lilly’s executive suite? [EndPoints]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

Study uncovers key parts of mechanism for activating T cells to fight cancer and other diseases [Dana-Farber Cancer Institute]

5.12.5 Immunothérapies - Pharma

OncoSec’s defense of weak preliminary Tavo data for PD-1 resistant melanoma can’t stop a rout [EndPoints]

5.2.1 Pharma - Partenariats

Janssen taps South Korea’s Yuhan for Tagrisso rival [FierceBiotech]

5.3 Traitements - FDA, EMA, NICE...

Meta-Analyses of Randomized Controlled Clinical Trials to Evaluate the Safety of Human Drugs or Biological Products Guidance for Industry [FDA]

Meta-Analyses of Randomized Trials: FDA Offers Draft Guidance [RAPS]

5.3.4 Traitements - AMM (FDA, EMA,...)

U.S. Food and Drug Administration Approves Empliciti® (elotuzumab) Plus Pomalidomide and Dexamethasone, a New Immunotherapy Combination for Certain Patients with Relapsed or Refractory Multiple Myeloma [BMS]

6.1 Observation

Linking a lie-in to breast cancer misreads the science [The Guardian]

The Key to a Long Life Has Little to Do With ‘Good Genes’ [Wired]

Life span has little to do with genes, analysis of large ancestry database shows [STAT]

6.7 DMP, Big Data & applis

Consumers may not like health data sharing, but pharma sure does [FiercePharma]

6.7.2 Applis

FDA’s MyStudies Application (App) [FDA]